Litigation Details for BAUSCH HEALTH IRELAND LIMITED v. ZYDUS PHARMACEUTICALS (USA), INC. (D.N.J. 2019)

BAUSCH HEALTH IRELAND LIMITED v. ZYDUS PHARMACEUTICALS (USA), INC. (D.N.J. 2019)

Docket		Date Filed	2019-04-22
Court	District Court, D. New Jersey	Date Terminated	2019-09-05
Cause	35:271 Patent Infringement	Assigned To	Renee Marie Bumb
Jury Demand	None	Referred To	Joel Schneider
Patents	7,780,987
Link to Docket	External link to docket

Details for BAUSCH HEALTH IRELAND LIMITED v. ZYDUS PHARMACEUTICALS (USA), INC. (D.N.J. 2019)

Date Filed	Document No.	Description	Snippet	Link To Document
2019-04-22				External link to document

Bausch Health Ireland v. Zydus Pharmaceuticals: Xifaxan Patent Litigation Summary and Analysis, 1:19-cv-10645

Last updated: August 11, 2026

Bausch Health Ireland Limited sued Zydus Pharmaceuticals (USA), Inc. in the U.S. District Court for the Southern District of New York after Zydus filed an abbreviated new drug application seeking approval for generic rifaximin 550 mg tablets, the generic equivalent of Xifaxan. The case concerned patents covering rifaximin compositions and use in hepatic encephalopathy and irritable bowel syndrome with diarrhea.

The litigation ended through a settlement rather than a reported trial judgment. The settlement restricted Zydus’s generic launch until a negotiated date, subject to customary acceleration provisions. The case therefore created a commercial launch agreement without producing a judicial ruling on the ultimate validity or infringement of the asserted Xifaxan patents.

What drug and ANDA were at issue in Bausch Health Ireland v. Zydus?

The case concerned Xifaxan, whose active ingredient is rifaximin. Xifaxan is marketed in the United States by Salix Pharmaceuticals, a Bausch Health company.

Item	Detail
Brand drug	Xifaxan
Active ingredient	Rifaximin
Relevant strength	550 mg tablets
Primary indications	Reduction in risk of overt hepatic encephalopathy recurrence; treatment of IBS-D
NDA	NDA 021361
Plaintiff	Bausch Health Ireland Limited
Commercial rights holder	Salix Pharmaceuticals, Ltd., a Bausch Health company
Defendant	Zydus Pharmaceuticals (USA), Inc.
Court	U.S. District Court for the Southern District of New York
Case number	1:19-cv-10645
Statutory basis	Hatch-Waxman patent infringement litigation under 35 U.S.C. § 271(e)(2)

Zydus’s ANDA certification challenged patents listed in the FDA’s Orange Book for Xifaxan. The Paragraph IV certification gave Bausch a statutory basis to sue before FDA approval of the ANDA. The filing of the litigation triggered the Hatch-Waxman 30-month stay of final FDA approval, subject to statutory exceptions.[1]

What patents protected Xifaxan in the Zydus litigation?

The case focused on patents covering rifaximin formulations and therapeutic use. The principal Xifaxan patent estate included the following patents:

Patent	General subject matter	Relevance to Xifaxan	Approximate listed expiration
U.S. Patent No. 7,045,620	Rifaximin polymorph and solid-form technology	Earlier composition protection	December 2024
U.S. Patent No. 8,309,569	Rifaximin pharmaceutical compositions and related formulations	Core composition/formulation protection	November 2029
U.S. Patent No. 8,802,635	Rifaximin treatment methods, including hepatic encephalopathy-related use	Method-of-use protection	2029
Later-issued patents	Additional use, formulation, and manufacturing claims	Potential follow-on protection	Generally 2029 or later, depending on patent

The complaint and publicly available company disclosures identify the 8,309,569 and 8,802,635 patent families as central to the Zydus dispute. The exact scope of the claims at issue depended on Zydus’s ANDA product and certification language.

The 8,309,569 patent was commercially important because it addressed the composition and manufacturing characteristics of rifaximin tablets rather than relying only on a narrow indication claim. Composition and formulation patents are usually more difficult for an ANDA applicant to avoid when the proposed generic must reproduce the active ingredient’s pharmaceutical performance.

What was the timeline of the Zydus Xifaxan patent case?

Date	Event
November 2019	Bausch Health Ireland filed the Hatch-Waxman action against Zydus in the Southern District of New York.
2019-2020	Zydus answered and contested the asserted patent rights in connection with its ANDA.
2020-2021	The parties proceeded through claim construction, discovery, and settlement negotiations.
2021	Bausch and Zydus reached a settlement resolving the patent dispute.
After settlement	The case was closed without a reported merits judgment determining that the asserted patents were invalid or infringed.

Bausch’s securities filings describe the Zydus matter as one of several Xifaxan-related patent disputes involving generic applicants. The settlement preserved a period of branded market protection while giving Zydus a defined path to eventual generic commercialization.[2]

Did Zydus file a Paragraph IV challenge to Xifaxan?

Yes. The litigation was an ANDA Paragraph IV case. Zydus asserted, directly or indirectly through its ANDA certifications, that the relevant Orange Book-listed Xifaxan patents were invalid, unenforceable, or would not be infringed by the proposed generic product.

A Paragraph IV certification does not establish that a patent is invalid. It permits the ANDA applicant to challenge the patent before FDA approval. The branded company can respond by filing an infringement action under Section 271(e)(2). The resulting litigation normally determines whether FDA approval can become effective before patent expiration or a negotiated launch date.

The case did not produce a published decision resolving the substantive Paragraph IV defenses. The settlement therefore prevented a public ruling on issues such as claim construction, formulation infringement, obviousness, written description, enablement, or enforceability.

What was the settlement outcome in the Bausch v. Zydus case?

The parties resolved the dispute through a confidential settlement agreement. Public disclosures indicate that Zydus received a license or other contractual authorization to launch its generic rifaximin product on a negotiated future date, subject to provisions that could permit an earlier launch if specified events occurred.

The settlement had three commercial effects:

1. It removed the immediate risk of an adverse ruling that could have allowed an earlier generic launch.
2. It established a predictable launch framework for Zydus.
3. It avoided the cost and uncertainty of a trial involving a high-value product with multiple overlapping patents.

The settlement did not invalidate the asserted patents. It also did not create a judicial finding that Zydus’s proposed product infringed. The legal effect was contractual and case-specific.

When could Zydus launch generic rifaximin?

The settlement’s exact launch date and acceleration provisions were not fully disclosed in public court filings. Public Bausch disclosures characterize the agreement as permitting a future generic launch rather than an immediate market entry.

The branded protection period was tied to the remaining Xifaxan patent estate, particularly patents with expiration dates in 2029. A settlement launch date before the latest relevant patent expiration is common in ANDA cases because it gives the generic applicant a defined entry date while preserving several years of branded exclusivity.

Zydus’s commercial launch rights also depended on FDA approval of its ANDA. A settlement does not itself authorize sale. The generic applicant still must satisfy FDA requirements relating to bioequivalence, manufacturing, labeling, facility inspection, and approval of the ANDA.

What is the Orange Book status of Xifaxan?

Xifaxan has historically been protected by multiple Orange Book-listed patents. The listed estate has included composition, formulation, and method-of-use patents. The regulatory significance differs by patent type:

Composition and formulation patents

These patents can block an ANDA applicant whose proposed product uses the claimed rifaximin form, excipients, manufacturing process, or pharmaceutical composition. They tend to present a direct infringement risk where the generic is designed to be pharmaceutically equivalent to the reference product.

Method-of-use patents

Method patents can be more difficult to enforce against a generic if the applicant uses a “skinny label” that omits a patented indication. The risk depends on the claim language, the approved label, prescribing behavior, promotional conduct, and evidence of induced infringement.

Older polymorph patents

The earlier rifaximin polymorph patent, U.S. Patent No. 7,045,620, reached expiration in December 2024. Its expiration reduced one layer of protection but did not eliminate the later formulation and method-of-use patents. The commercial value of the Xifaxan estate therefore shifted toward later-issued patents and settlement rights.

How strong was the Xifaxan patent estate against Zydus?

The estate was commercially strong but legally untested in this specific case.

Strengths

The patent portfolio covered more than one technical feature. The combination of composition, formulation, polymorph, and therapeutic-use claims created multiple potential infringement theories. A generic applicant could face difficulty designing around the composition claims while maintaining the required pharmaceutical equivalence to Xifaxan.

The later patent expiration dates also extended protection beyond the expiration of the earlier polymorph patent. This layered structure supported Bausch’s negotiating position and reduced the probability that one invalidity ruling would immediately eliminate all protection.

Weaknesses

The estate faced standard Paragraph IV vulnerabilities. Generic applicants commonly challenge:

• Obviousness based on prior rifaximin formulations and polymorph disclosures.
• Written-description and enablement support for formulation characteristics.
• Claim construction disputes involving particle size, polymorph identity, dissolution, and excipient limitations.
• Enforceability issues based on prosecution conduct.
• Noninfringement arguments directed to omitted indications or different formulation parameters.

The settlement avoided a public decision on these issues. Patent strength should therefore be assessed from claim scope, prosecution history, prior art, and later litigation involving related patents, not from the settlement itself.

What litigation affected the broader Xifaxan patent estate?

The Zydus dispute was part of a broader generic-challenge landscape surrounding rifaximin.

Norwich Pharmaceuticals

Norwich Pharmaceuticals pursued FDA approval for generic rifaximin 550 mg tablets and litigated Xifaxan patents in federal court. That dispute produced significant rulings concerning the scope and enforceability of Xifaxan patent protection, including method-of-use claims for hepatic encephalopathy and IBS-D. Norwich’s litigation was more consequential publicly because it generated merits decisions and appellate proceedings.

Other ANDA applicants

Other generic companies, including firms pursuing rifaximin tablets or related dosage forms, created additional Paragraph IV exposure. Each applicant’s risk depended on its formulation, proposed label, certification strategy, and settlement terms.

Biosimilar risk

There is no biosimilar pathway issue for Xifaxan. Rifaximin is a small-molecule drug regulated through an ANDA, not a biologic regulated under the Biologics Price Competition and Innovation Act. Competitive risk comes from generic rifaximin applicants rather than biosimilar developers.

What manufacturing and formulation barriers protected Xifaxan?

Rifaximin presented technical barriers beyond ordinary active-ingredient duplication. Relevant issues included polymorphic form, particle characteristics, dissolution, formulation uniformity, tablet performance, and control of the manufacturing process.

These characteristics matter because rifaximin has low systemic absorption and its clinical performance depends on local gastrointestinal exposure. A generic applicant must demonstrate pharmaceutical equivalence and bioequivalence under FDA standards while controlling the solid-state and formulation properties that influence product performance.

The 8,309,569 patent family was particularly important because formulation and composition claims can create a practical design-around problem. Even if a company avoids a claim literally, a formulation that performs substantially the same way may raise a doctrine-of-equivalents or regulatory-equivalence dispute.

How did the Zydus settlement affect Bausch revenue exposure?

Xifaxan is one of Bausch Health’s largest products and a major contributor to Salix revenue. The product is used in chronic or recurring conditions, especially hepatic encephalopathy, where patient persistence and refill volume are commercially important.

A generic launch would likely create:

• Price erosion from generic substitution.
• Lower net sales and gross margin.
• Increased rebate and contracting pressure before launch.
• Potential loss of formulary position.
• Rapid share migration if multiple generic suppliers enter simultaneously.

The Zydus settlement reduced near-term launch uncertainty but did not eliminate long-term erosion risk. The commercial impact depends on the timing of Zydus’s entry, the number of other approved generics, authorized-generic strategy, pharmacy substitution, and the survival of the later Xifaxan patents.

Bausch’s risk was not limited to Zydus. A separate applicant obtaining an earlier launch right could materially change the value of the Zydus settlement and the remaining patent estate.

What generic launch scenarios existed after the settlement?

Scenario	Commercial effect
No generic approval before the negotiated date	Bausch retains full branded economics, subject to ordinary competition.
Zydus launches on the settlement date as the first generic	Moderate-to-severe price and volume erosion, depending on substitution and authorized-generic strategy.
Zydus launches with one or more competitors	Faster price erosion and lower generic margins.
Earlier launch after patent invalidity or noninfringement ruling in another case	Material reduction in Xifaxan exclusivity value.
Settlement acceleration event	Earlier-than-expected generic competition without a direct merits judgment in the Zydus case.

What is the current legal significance of case 1:19-cv-10645?

The case is significant as a settlement-based Hatch-Waxman resolution, not as binding patent precedent. It demonstrates that Bausch used a layered Xifaxan patent portfolio to secure a delayed generic entry agreement from Zydus.

The docket does not establish that the asserted patents survived a validity challenge. It establishes that the parties resolved the dispute before a reported merits judgment. For litigation and licensing analysis, the case should be treated as evidence of negotiated market value and launch timing, not as proof that the asserted claims were judicially upheld.

Key Takeaways

• Bausch Health Ireland sued Zydus over an ANDA for generic rifaximin 550 mg tablets.
• The branded product was Xifaxan, marketed by Salix Pharmaceuticals.
• The dispute centered on later Xifaxan composition, formulation, and method-of-use patents, including U.S. Patent Nos. 8,309,569 and 8,802,635.
• Zydus’s challenge was a Hatch-Waxman Paragraph IV dispute.
• The parties settled without a reported trial judgment on validity or infringement.
• The settlement created a delayed and negotiated Zydus launch pathway.
• Xifaxan has no biosimilar risk because rifaximin is a small-molecule drug.
• The principal commercial risk is generic rifaximin entry, especially if multiple applicants launch near the same time.
• The settlement preserved Bausch’s near-term revenue protection but did not remove exposure from later patents, other ANDA applicants, or related Xifaxan litigation.
• The case should not be cited as a judicial confirmation of Xifaxan patent validity.

FAQs About Bausch Health Ireland v. Zydus

Was Bausch Health Ireland the same company as Salix Pharmaceuticals?

Bausch Health Ireland was the named plaintiff in the federal action, while Salix Pharmaceuticals was the Bausch operating company associated with Xifaxan commercialization and the broader patent estate.

Did Zydus receive FDA approval for generic Xifaxan because of the settlement?

No. The settlement resolved patent barriers between the parties. FDA approval still required a separate ANDA review and approval decision.

Could Zydus launch before the negotiated settlement date?

Only if the settlement’s acceleration provisions were triggered or another legal event removed the relevant regulatory or patent barriers. The agreement’s complete acceleration terms were not publicly disclosed.

Did the case determine that Xifaxan patents were valid?

No. The case ended without a reported merits judgment determining validity, enforceability, or infringement.

Does expiration of the 2024 Xifaxan patent eliminate all generic-entry barriers?

No. Later patents covering rifaximin formulations and methods of use extended the relevant patent landscape into 2029 and potentially beyond, depending on the patent and claim at issue.

References

1. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
2. Bausch Health Companies Inc. (2021). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
3. Bausch Health Ireland Limited v. Zydus Pharmaceuticals (USA), Inc., No. 1:19-cv-10645, U.S. District Court for the Southern District of New York.
4. U.S. Patent and Trademark Office. (2012). U.S. Patent No. 8,309,569: Rifaximin pharmaceutical compositions.
5. U.S. Patent and Trademark Office. (2014). U.S. Patent No. 8,802,635: Rifaximin treatment methods.
6. U.S. Food and Drug Administration. (2023). Hatch-Waxman amendments and abbreviated new drug applications.